Janssen veterans raise $13M for Centyrin platform

Aro Biotherapeutics Co. (Philadelphia, Pa.) unveiled the lead programs from its Centyrin pipeline on Dec. 11, along with a $13 million seed round from Johnson & Johnson Innovation - JJDC Inc. and BioMotiv LLC (Cleveland, Ohio).

Former Johnson & Johnson (NYSE:JNJ) executives CEO Susan Dillon and CSO Karyn O’Neil launched Aro to develop Centyrins for extra-hepatic, receptor-mediated delivery of oligonucleotides and other payloads (see “J&J Execs Launch Centyrins Newco Aro”)...